| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ORIGINAL PAPER |
Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
Correspondence: Susan E. Bates, M.D., Molecular Therapeutics Section, Cancer Therapeutics Branch, Building 10 Room 12N226, 9000 Rockville Pike, Bethesda, Maryland 20892, USA. Telephone: 301-402-1357; Fax: 301-402-1608; e-mail: sebates{at}helix.nih.gov
Drug resistance remains one of the primary causes of suboptimal outcomes in cancer therapy. ATP-binding cassette (ABC) transporters are a family of transporter proteins that contribute to drug resistance via ATP-dependent drug efflux pumps. P-glycoprotein (P-gp), encoded by the MDR1 gene, is an ABC transporter normally involved in the excretion of toxins from cells. It also confers resistance to certain chemotherapeutic agents. P-gp is overexpressed at baseline in chemotherapy-resistant tumors, such as colon and kidney cancers, and is upregulated after disease progression following chemotherapy in malignancies such as leukemia and breast cancer. Other transporter proteins mediating drug resistance include those in the multidrug-resistance-associated protein (MRP) family, notably MRP1, and ABCG2. These transporters are also involved in normal physiologic functions. The expressions of MRP family members and ABCG2 have not been well worked out in cancer.
Increased drug accumulation and drug resistance reversal with P-gp inhibitors have been well documented in vitro, but only suggested in clinical trials. Limitations in the design of early resistance reversal trials contributed to disappointing results. Despite this, three randomized trials have shown statistically significant benefits with the use of a P-gp inhibitor in combination with chemotherapy. Improved diagnostic techniques aimed at the selection of patients with tumors that express P-gp should result in more successful outcomes. Further optimism is warranted with the advent of potent, nontoxic inhibitors and new treatment strategies, including the combination of new targeted therapies with therapies aimed at the prevention of drug resistance.
This article has been cited by other articles:
 |
|
 |
|
  A. L. Risinger, E. M. Jackson, L. A. Polin, G. L. Helms, D. A. LeBoeuf, P. A. Joe, E. Hopper-Borge, R. F. Luduena, G. D. Kruh, and S. L. Mooberry The Taccalonolides: Microtubule Stabilizers That Circumvent Clinically Relevant Taxane Resistance Mechanisms Cancer Res., November 1, 2008; 68(21): 8881 - 8888. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Miller, B. Bauer, and A. M. S. Hartz Modulation of P-Glycoprotein at the Blood-Brain Barrier: Opportunities to Improve Central Nervous System Pharmacotherapy Pharmacol. Rev., June 1, 2008; 60(2): 196 - 209. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Winter, D. M. Lovato, H. M. Khawaja, B. S. Edwards, I. D. Steele, S. M. Young, T. I. Oprea, L. A. Sklar, and R. S. Larson High-Throughput Screening for Daunorubicin-Mediated Drug Resistance Identifies Mometasone Furoate as a Novel ABCB1-Reversal Agent J Biomol Screen, March 1, 2008; 13(3): 185 - 193. [Abstract] [PDF]
|
|
|
|
 |
|
 S. P. Newman, P. A. Foster, C. Stengel, J. M. Day, Y. T. Ho, J.-G. Judde, M. Lassalle, G. Prevost, M. P. Leese, B. V.L. Potter, et al. STX140 Is Efficacious In vitro and In vivo in Taxane-Resistant Breast Carcinoma Cells Clin. Cancer Res., January 15, 2008; 14(2): 597 - 606. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Lu and C. Klaassen Gender Differences in mRNA Expression of ATP-Binding Cassette Efflux and Bile Acid Transporters in Kidney, Liver, and Intestine of 5/6 Nephrectomized Rats Drug Metab. Dispos., January 1, 2008; 36(1): 16 - 23. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Masuyama, H. Nakatsukasa, N. Takamoto, and Y. Hiramatsu Down-Regulation of Pregnane X Receptor Contributes to Cell Growth Inhibition and Apoptosis by Anticancer Agents in Endometrial Cancer Cells Mol. Pharmacol., October 1, 2007; 72(4): 1045 - 1053. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Winter, Z. Jiang, H. M. Khawaja, T. Griffin, M. Devidas, B. L. Asselin, and R. S. Larson Identification of genomic classifiers that distinguish induction failure in T-lineage acute lymphoblastic leukemia: a report from the Children's Oncology Group Blood, September 1, 2007; 110(5): 1429 - 1438. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Rottenberg, A. O. H. Nygren, M. Pajic, F. W. B. van Leeuwen, I. van der Heijden, K. van de Wetering, X. Liu, K. E. de Visser, K. G. Gilhuijs, O. van Tellingen, et al. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer PNAS, July 17, 2007; 104(29): 12117 - 12122. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kasibhatla, V. Baichwal, S. X. Cai, B. Roth, I. Skvortsova, S. Skvortsov, P. Lukas, N. M. English, N. Sirisoma, J. Drewe, et al. MPC-6827: A Small-Molecule Inhibitor of Microtubule Formation That Is Not a Substrate for Multidrug Resistance Pumps Cancer Res., June 15, 2007; 67(12): 5865 - 5871. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Saeki, T. Nomizu, M. Toi, Y. Ito, S. Noguchi, T. Kobayashi, T. Asaga, H. Minami, N. Yamamoto, K. Aogi, et al. Dofequidar Fumarate (MS-209) in Combination With Cyclophosphamide, Doxorubicin, and Fluorouracil for Patients With Advanced or Recurrent Breast Cancer J. Clin. Oncol., February 1, 2007; 25(4): 411 - 417. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Goda, F. Fenyvesi, Z. Bacso, H. Nagy, T. Marian, A. Megyeri, Z. Krasznai, I. Juhasz, M. Vecsernyes, and G. Szabo Jr. Complete Inhibition of P-glycoprotein by Simultaneous Treatment with a Distinct Class of Modulators and the UIC2 Monoclonal Antibody J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 81 - 88. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Calcabrini, J. M. Garcia-Martinez, L. Gonzalez, M. J. Tendero, M. T. A. Ortuno, P. Crateri, A. Lopez-Rivas, G. Arancia, P. Gonzalez-Porque, and J. Martin-Perez Inhibition of proliferation and induction of apoptosis in human breast cancer cells by lauryl gallate Carcinogenesis, August 1, 2006; 27(8): 1699 - 1712. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. G. Deeley, C. Westlake, and S. P. C. Cole Transmembrane Transport of Endo- and Xenobiotics by Mammalian ATP-Binding Cassette Multidrug Resistance Proteins. Physiol Rev, July 1, 2006; 86(3): 849 - 899. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Sekine, H. Miyazaki, and H. Endou Molecular physiology of renal organic anion transporters Am J Physiol Renal Physiol, February 1, 2006; 290(2): F251 - F261. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. L. Dalton, J. T. Collins, T. C. Barnett, and J. R. Scott RscA, a Member of the MDR1 Family of Transporters, Is Repressed by CovR and Required for Growth of Streptococcus pyogenes under Heat Stress J. Bacteriol., January 1, 2006; 188(1): 77 - 85. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Miki, T. Suzuki, K. Kitada, N. Yabuki, R. Shibuya, T. Moriya, T. Ishida, N. Ohuchi, B. Blumberg, and H. Sasano Expression of the Steroid and Xenobiotic Receptor and Its Possible Target Gene, Organic Anion Transporting Polypeptide-A, in Human Breast Carcinoma Cancer Res., January 1, 2006; 66(1): 535 - 542. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N Chassaing, L Martin, P Calvas, M Le Bert, and A Hovnanian Pseudoxanthoma elasticum: a clinical, pathophysiological and genetic update including 11 novel ABCC6 mutations J. Med. Genet., December 1, 2005; 42(12): 881 - 892. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Langer, K. Specht, K. Becker, P. Ewald, M. Bekesch, M. Sarbia, R. Busch, M. Feith, H. J. Stein, J.-R. Siewert, et al. Association of Pretherapeutic Expression of Chemotherapy-Related Genes with Response to Neoadjuvant Chemotherapy in Barrett Carcinoma Clin. Cancer Res., October 15, 2005; 11(20): 7462 - 7469. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Monte, M. R. Ballestero, O. Briz, M. J. Perez, and J. J. G. Marin Proapoptotic Effect on Normal and Tumor Intestinal Cells of Cytostatic Drugs with Enterohepatic Organotropism J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 24 - 35. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. S. Donnenberg and A. D. Donnenberg Multiple Drug Resistance in Cancer Revisited: The Cancer Stem Cell Hypothesis J. Clin. Pharmacol., August 1, 2005; 45(8): 872 - 877. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Pratt, R. L. Shepard, R. A. Kandasamy, P. A. Johnston, W. Perry III, and A. H. Dantzig The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites Mol. Cancer Ther., May 1, 2005; 4(5): 855 - 863. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Johnson, E. M. Shepard, and K. W. Scotto Differential Regulation of MDR1 Transcription by the p53 Family Members: ROLE OF THE DNA BINDING DOMAIN J. Biol. Chem., April 8, 2005; 280(14): 13213 - 13219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Ifergan, G. Jansen, and Y. G. Assaraf Cytoplasmic Confinement of Breast Cancer Resistance Protein (BCRP/ABCG2) as a Novel Mechanism of Adaptation to Short-Term Folate Deprivation Mol. Pharmacol., April 1, 2005; 67(4): 1349 - 1359. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Dixit, B. Zingarelli, D. J. Buckley, A. R. Buckley, and G. M. Pauletti Nitric oxide mediates increased P-glycoprotein activity in interferon-{gamma}-stimulated human intestinal cells Am J Physiol Gastrointest Liver Physiol, March 1, 2005; 288(3): G533 - G540. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Duffy Predictive Markers in Breast and Other Cancers: A Review Clin. Chem., March 1, 2005; 51(3): 494 - 503. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Thomas, L. Wang, R. E. Clark, and M. Pirmohamed Active transport of imatinib into and out of cells: implications for drug resistance Blood, December 1, 2004; 104(12): 3739 - 3745. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| THE ONCOLOGIST | STEM CELLS | CME | ALPHAMED PRESS JOURNALS |
